Developing idiotype vaccines for lymphoma: From preclinical studies to phase III clinical trials

British Journal of Haematology

Volumn 142, Issue 2, 2008, Pages 179-191

  Park, Hyun Jun ^a   Neelapu, Sattva S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Idiotype; Immunotherapy; Lymphoma; Non Hodgkin lymphoma; Vaccine

Indexed keywords

CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DNA VACCINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN IDIOTYPE; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; LIPOSOME; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER SURVIVAL; CLINICAL TRIAL; DENDRITIC CELL; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FOLLICULAR LYMPHOMA; HUMAN; HYBRIDOMA; IMMUNE RESPONSE; IMMUNOGENICITY; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN INDURATION; TREATMENT RESPONSE; VACCINE PRODUCTION;

ANTIBODY FORMATION; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY, ACTIVE; LYMPHOMA, NON-HODGKIN; MODELS, IMMUNOLOGICAL; VACCINES, DNA;

EID: 47249094575     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07143.x     Document Type: Review

References (94)

1. Barnett, B., Kryczek, I., Cheng, P., Zou, W. Curiel, T.J. (2005) Regulatory T cells in ovarian cancer: biology and therapeutic potential. American Journal of Reproductive Immunology, 54, 369 377.
2. Barrios, Y., Cabrera, R., Yanez, R., Briz, M., Plaza, A., Fores, R., Fernandez, M.N. Diaz-Espada, F. (2002) Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica, 87, 400 407.
3. Baskar, S., Kobrin, C.B. Kwak, L.W. (2004) Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. Journal of Clinical Investigation, 113, 1498 1510.
4. Bendandi, M., Gocke, C.D., Kobrin, C.B., Benko, F.A., Sternas, L.A., Pennington, R., Watson, T.M., Reynolds, C.W., Gause, B.L., Duffey, P.L., Jaffe, E.S., Creekmore, S.P., Longo, D.L. Kwak, L.W. (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Medicine, 5, 1171 1177.
5. Bennett, S.R., Carbone, F.R., Toy, T., Miller, J.F. Heath, W.R. (1998) B cells directly tolerize CD8(+) T cells. Journal of Experimental Medicine, 188, 1977 1983.
6. Benvenuti, F. Burrone, O.R. (2001) Anti-idiotypic antibodies induced by genetic immunisation are directed exclusively against combined V(L)/V(H) determinants. Gene Therapy, 8, 1555 1561.
7. Benvenuti, F., Burrone, O.R. Efremov, D.G. (2000) Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection. Gene Therapy, 7, 605 611.
8. Benvenuti, F., Cesco-Gaspere, M. Burrone, O.R. (2002) Anti-idiotypic DNA vaccines for B-cell lymphoma therapy. Frontiers in Bioscience, 7, d228 d234 Review.
9. Bertinetti, C., Zirlik, K., Heining-Mikesch, K., Ihorst, G., Dierbach, H., Waller, C.F. Veelken, H. (2006) Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Cancer Research, 66, 4496 4502.
10. Biragyn, A., Tani, K., Grimm, M.C., Weeks, S. Kwak, L.W. (1999) Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent anti-tumor immunity. Nature Biotechnology, 17, 253 258.
11. Carroll, W.L., Thielemans, K., Dilley, J. Levy, R. (1986) Mouse x human heterohybridomas as fusion partners with human B cell tumors. Journal of Immunological Methods, 89, 61 72.
12. Cesco-Gaspere, M., Benvenuti, F. Burrone, O.R. (2005) BCL1 lymphoma protection induced by idiotype DNA vaccination is entirely dependent on anti-idiotypic antibodies. Cancer Immunology and Immunotherapy, 54, 351 358.
13. Colombat, P., Salles, G., Brousse, N., Eftekhari, P., Soubeyran, P., Delwail, V., Deconinck, E., Haioun, C., Foussard, C., Sebban, C., Stamatoullas, A., Milpied, N., Boue, F., Taillan, B., Lederlin, P., Najman, A., Thieblemont, C., Montestruc, F., Mathieu-Boue, A., Benzohra, A. Solal-Celigny, P. (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood, 97, 101 106.
14. Dannull, J., Su, Z., Rizzieri, D., Yang, B.K., Coleman, D., Yancey, D., Zhang, A., Dahm, P., Chao, N., Gilboa, E. Vieweg, J. (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. Journal of Clinical Investigation, 115, 3623 3633.
15. Dave, S.S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R.D., Chan, W.C., Fisher, R.I., Braziel, R.M., Rimsza, L.M., Grogan, T.M., Miller, T.P., LeBlanc, M., Greiner, T.C., Weisenburger, D.D., Lynch, J.C., Vose, J., Armitage, J.O., Smeland, E.B., Kvaloy, S., Holte, H., Delabie, J., Connors, J.M., Lansdorp, P.M., Ouyang, Q., Lister, T.A., Davies, A.J., Norton, A.J., Muller-Hermelink, H.K., Ott, G., Campo, E., Montserrat, E., Wilson, W.H., Jaffe, E.S., Simon, R., Yang, L., Powell, J., Zhao, H., Goldschmidt, N., Chiorazzi, M. Staudt, L.M. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. New England Journal of Medicine, 351, 2159 2169.
16. Dessureault, S., Noyes, D., Lee, D., Dunn, M., Janssen, W., Cantor, A., Sotomayor, E., Messina, J. Antonia, S.J. (2007) A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Annals of Surgical Oncology, 14, 869 884.
17. Eager, R. Nemunaitis, J. (2005) GM-CSF gene-transduced tumor vaccines. Molecular Therapeutics, 12, 18 27.
18. El-Amine, M., Melo, M., Kang, Y., Nguyen, H., Qian, J. Scott, D.W. (2000) Mechanisms of tolerance induction by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells. Journal of Immunology, 165, 5631 5636.
19. van Essen, D., Dullforce, P., Brocker, T. Gray, D. (2000) Cellular interactions involved in Th cell memory. Journal of Immunology, 165, 3640 3646.
20. Eynon, E.E. Parker, D.C. (1992) Small B-cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. Journal of Experimental Medicine, 175, 131 138.
21. Freedman, P.M., Autry, J.R., Tokuda, S. Williams, Jr., R.C. (1976) Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein. Journal of the National Cancer Institute, 56, 735 740.
22. Gajewski, T.F., Pinnas, M., Wong, T. Fitch, F.W. (1991) Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations. Journal of Immunology, 146, 1750 1758.
23. Harding, C.V., Collins, D.S., Kanagawa, O. Unanue, E.R. (1991) Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. Journal of Immunology, 147, 2860 2863.
24. Harris, J.R. Markl, J. (2000) Keyhole limpet hemocyanin: molecular structure of a potent marine immunoactivator. A review. European Urology, 37 (Suppl. 3 24 33.
25. Hawkins, R.E., Winter, G., Hamblin, T.J., Stevenson, F.K. Russell, S.J. (1993) A genetic approach to idiotypic vaccination. Journal of Immunotherapy, 14, 273 278.
26. Hawkins, R.E., Zhu, D., Ovecka, M., Winter, G., Hamblin, T.J., Long, A. Stevenson, F.K. (1994) Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood, 83, 3279 3288.
27. Horning, S.J. Rosenberg, S.A. (1984) The natural history of initially untreated low-grade non-Hodgkin's lymphomas. New England Journal of Medicine, 311, 1471 1475.
28. Hsu, F.J., Benike, C., Fagnoni, F., Liles, T.M., Czerwinski, D., Taidi, B., Engleman, E.G. Levy, R. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Medicine, 2, 52 58.
29. Hsu, F.J., Caspar, C.B., Czerwinski, D., Kwak, L.W., Liles, T.M., Syrengelas, A., Taidi-Laskowski, B. Levy, R. (1997) Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood, 89, 3129 3135.
30. Hurvitz, S.A. Timmerman, J.M. (2005) Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId. Expert Opinion on Biological Therapy, 5, 841 852.
31. Inoges, S., Rodriguez-Calvillo, M., Zabalegui, N., Lopez-Diaz de Cerio, A., Villanueva, H., Soria, E., Suarez, L., Rodriguez-Caballero, A., Pastor, F., Garcia-Munoz, R., Panizo, C., Perez-Calvo, J., Melero, I., Rocha, E., Orfao, A. Bendandi, M. (2006) Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. Journal of the National Cancer Institute, 98, 1292 1301.
32. Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T. Minato, N. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proceedings of the National Academy of Sciences of the United States of America, 99, 12293 12297.
33. Iwai, Y., Terawaki, S. Honjo, T. (2005) PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. International Immunology, 17, 133 144.
34. Kaledin, V.I., Matienko, N.A., Nikolin, V.P., Gruntenko, Y.V., Budker, V.G. Vakhrusheva, T.E. (1982) Subcutaneously injected radiolabeled liposomes: transport to the lymph nodes in mice. Journal of the National Cancer Institute, 69, 67 71.
35. Kaleem, Z., Zehnbauer, B.A., White, G. Zutter, M.M. (2000) Lack of expression of surface immunoglobulin light chains in B-cell non-Hodgkin lymphomas. American Journal of Clinical Pathology, 113, 399 405.
36. Kaminski, M.S., Kitamura, K., Maloney, D.G. Levy, R. (1987) Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. Journal of Immunology, 138, 1289 1296.
37. Kanter, G., Yang, J., Voloshin, A., Levy, S., Swartz, J.R. Levy, R. (2007) Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. Blood, 109, 3393 3399.
38. Keilholz, U., Weber, J., Finke, J.H., Gabrilovich, D.I., Kast, W.M., Disis, M.L., Kirkwood, J.M., Scheibenbogen, C., Schlom, J., Maino, V.C., Lyerly, H.K., Lee, P.P., Storkus, W., Marincola, F., Worobec, A. Atkins, M.B. (2002) Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. Journal of Immunotherapy (1997), 25, 97 138.
39. King, C.A., Spellerberg, M.B., Zhu, D., Rice, J., Sahota, S.S., Thompsett, A.R., Hamblin, T.J., Radl, J. Stevenson, F.K. (1998) DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nature Medicine, 4, 1281 1286.
40. ® (Id/KLH) vaccine following rituximab. Blood (ASH Annual Meeting Abstracts), 106, Abstract 772.
41. Küppers, R. (2005) Mechanisms of B-cell lymphoma pathogenesis. Nature Reviews Cancer, 5, 251 262.
42. Kwak, L.W., Campbell, M.J., Zelenetz, A.D. Levy, R. (1990) Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin. Blood, 76, 2411 2417.
43. Kwak, L.W., Campbell, M.J., Czerwinski, D.K., Hart, S., Miller, R.A. Levy, R. (1992) Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. New England Journal of Medicine, 327, 1209 1215.
44. Kwak, L.W., Young, H.A., Pennington, R.W. Weeks, S.D. (1996) Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proceedings of the National Academy of Sciences of the United States of America, 93, 10972 10977.
45. Kwak, L.W., Pennington, R., Boni, L., Ochoa, A.C., Robb, R.J. Popescu, M.C. (1998) Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. Journal of Immunology, 160, 3637 3641.
46. Lambert, S.L., Okada, C.Y. Levy, R. (2004) TCR vaccines against a murine T cell lymphoma: a primary role for antibodies of the IgG2c class in tumor protection. Journal of Immunology, 172, 929 936.
47. Lee, S.T., Jiang, Y.F., Park, K.U., Woo, A.F. Neelapu, S.S. (2007) BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma. Expert Opinion on Biological Therapy, 7, 113 122.
48. Levitsky, H.I., Montgomery, J., Ahmadzadeh, M., Staveley-O'Carroll, K., Guarnieri, F., Longo, D.L. Kwak, L.W. (1996) Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. Journal of Immunology, 156, 3858 3865.
49. Li, S., Eshleman, J.R. Borowitz, M.J. (2002) Lack of surface immunoglobulin light chain expression by flow cytometric immunophenotyping can help diagnose peripheral B-cell lymphoma. American Journal of Clinical Pathology, 118, 229 234.
50. Linton, P.J., Harbertson, J. Bradley, L.M. (2000) A critical role for B-cells in the development of memory CD4 cells. Journal of Immunology, 165, 5558 5565.
51. Longo, D.L., Duffey, P.L., Gribben, J.G., Jaffe, E.S., Curti, B.D., Gause, B.L., Janik, J.E., Braman, V.M., Esseltine, D., Wilson, W.H., Kaufman, D., Wittes, R.E., Nadler, L.M. Urba, W.J. (2000) Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study. Cancer Journal, 6, 146 150.
52. Lynch, R.G., Graff, R.J., Sirisinha, S., Simms, E.S. Eisen, H.N. (1972) Myeloma proteins as tumor-specific transplantation antigens. Proceedings of the National Academy of Sciences of the United States of America, 69, 1540 1544.
53. Maier, T., Tun-Kyi, A., Tassis, A., Jungius, K.P., Burg, G., Dummer, R. Nestle, F.O. (2003) Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood, 102, 2338 2344.
54. Maloney, D.G., Liles, T.M., Czerwinski, D.K., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A. Levy, R. (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood, 84, 2457 2466.
55. ®, Id-KLH). Blood, 110, 3416.
56. Malyguine, A., Strobl, S.L., Shafer-Weaver, K.A., Ulderich, T., Troke, A., Baseler, M., Kwak, L.W. Neelapu, S.S. (2004) A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. Journal of Translational Medicine, 2, 9.
57. McCormick, A.A., Kumagai, M.H., Hanley, K., Turpen, T.H., Hakim, I., Grill, L.K., Tuse, D., Levy, S. Levy, R. (1999) Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proceedings of the National Academy of Sciences of the United States of America, 96, 703 708.
58. McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 2825 2833.
59. + T cells in follicular lymphoma and is associated with T-cell exhaustion. Blood (ASH Annual Meeting Abstracts), 110, 2749.
60. Neelapu, S.S., Baskar, S., Gause, B.L., Kobrin, C.B., Watson, T.M., Frye, A.R., Pennington, R., Harvey, L., Jaffe, E.S., Robb, R.J., Popescu, M.C. Kwak, L.W. (2004) Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clinical Cancer Research, 10, 8309 8317.
61. Neelapu, S.S., Kwak, L.W., Kobrin, C.B., Reynolds, C.W., Janik, J.E., Dunleavy, K., White, T., Harvey, L., Pennington, R., Stetler-Stevenson, M., Jaffe, E.S., Steinberg, S.M., Gress, R., Hakim, F. Wilson, W.H. (2005a) Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nature Medicine, 11, 986 991.
62. Neelapu, S.S., Gause, B.L., Nikcevich, D.A., Schuster, S.J., Winter, J., Gockerman, J.P., Loughran, Jr., T., Takeshita, K., Inghirami, G., McGaughey, D., Watson, T.M., Snow, S., Kubovic, P., Ferraro, M., Jones, E., Jaffe, E.S., Schwartzentruber, D.J., Danforth, D., Sherry, R., Kass, E., Van Waes, C., Reynolds, C.W. Kwak, L.J. (2005b) Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report. Clinical Lymphoma, 6, 61 64.
63. Neelapu, S.S., Lee, S.T., Qin, H., Cha, S.C., Woo, A.F. Kwak, L.W. (2006) Therapeutic lymphoma vaccines: importance of T-cell immunity. Expert Review of Vaccines, 5, 381 394.
64. Neelapu, S.S., Gause, B.L., Harvey, L., Lee, S.T., Frye, A.R., Horton, J., Robb, R.J., Popescu, M.C. Kwak, L.W. (2007) A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood, 109, 5160 5163.
65. Nelson, E.L., Li, X., Hsu, F.J., Kwak, L.W., Levy, R., Clayberger, C. Krensky, A.M. (1996) Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood, 88, 580 589.
66. O'Mahony, D., Morris, J.C., Quinn, C., Gao, W., Wilson, W.H., Gause, B., Pittaluga, S., Neelapu, S., Brown, M., Fleisher, T.A., Gulley, J.L., Schlom, J., Nussenblatt, R., Albert, P., Davis, T.A., Lowy, I., Petrus, M., Waldmann, T.A. Janik, J.E. (2007) A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clinical Cancer Research, 13, 958 964.
67. Oki, Y., McLaughlin, P., Fayad, L.E., Pro, B., Mansfield, P.F., Clayman, G.L., Medeiros, L.J., Kwak, L.W., Srivastava, P.K. Younes, A. (2007) Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer, 109, 77 83.
68. Oussoren, C. Storm, G. (2001) Liposomes to target the lymphatics by subcutaneous administration. Advanced Drug Delivery Reviews, 50, 143 156.
69. Popescu, M.C., Robb, R.J., Batenjany, M.M., Boni, L.T., Neville, M.E., Pennington, R.W., Neelapu, S.S. Kwak, L.W. (2007) A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. Blood, 109, 5407 5410.
70. Qin, Z., Richter, G., Schuler, T., Ibe, S., Cao, X. Blankenstein, T. (1998) B cells inhibit induction of T cell-dependent tumor immunity. Nature Medicine, 4, 627 630.
71. Rao, M. Alving, C.R. (2000) Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army. mil. Advanced Drug Delivery Reviews, 41, 171 188.
72. Redfern, C.H., Guthrie, T.H., Bessudo, A., Densmore, J.J., Holman, P.R., Janakiraman, N., Leonard, J.P., Levy, R.L., Just, R.G., Smith, M.R., Rosenfelt, F.P., Wiernik, P.H., Carter, W.D., Gold, D.P., Melink, T.J., Gutheil, J.C. Bender, J.F. (2006) Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. Journal of Clinical Oncology, 24, 3107 3112.
73. Rivera, A., Chen, C.C., Ron, N., Dougherty, J.P. Ron, Y. (2001) Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. International Immunology, 13, 1583 1593.
74. TM vaccine therapy of follicular lymphoma in first remission: long-term follow-up of a phase II trial and status of a controlled, randomized phase III trial. Blood, 106, 2441.
75. Shen, H., Whitmire, J.K., Fan, X., Shedlock, D.J., Kaech, S.M. Ahmed, R. (2003) A specific role for B cells in the generation of CD8 T cell memory by recombinant Listeria monocytogenes. Journal of Immunology, 170, 1443 1451.
76. Steinman, R.M. (1991) The dendritic cell system and its role in immunogenicity. Annual Review of Immunology, 9, 271 296.
77. Stevenson, G.T. Stevenson, F.K. (1975) Antibody to a molecularly-defined antigen confined to a tumour cell surface. Nature, 254, 714 716.
78. Stevenson, G.T., Elliott, E.V. Stevenson, F.K. (1977) Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target. Federation Proceedings, 36, 2268 2271.
79. Sutmuller, R.P., van Duivenvoorde, L.M., van Elsas, A., Schumacher, T.N., Wildenberg, M.E., Allison, J.P., Toes, R.E., Offringa, R. Melief, C.J. (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. Journal of Experimental Medicine, 194, 823 832.
80. Thomson, K.J. Mackinnon, S. (2006) Role of allogeneic transplantation in low-grade lymphoma and chronic lymphocytic leukemia. Current Opinion in Hematology, 13, 273 279.
81. Timmerman, J.M. Levy, R. (2000) Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. Journal of Immunology, 164, 4797 4803.
82. Timmerman, J.M., Caspar, C.B., Lambert, S.L., Syrengelas, A.D. Levy, R. (2001) Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood, 97, 1370 1377.
83. Timmerman, J.M., Czerwinski, D.K., Davis, T.A., Hsu, F.J., Benike, C., Hao, Z.M., Taidi, B., Rajapaksa, R., Caspar, C.B., Okada, C.Y., van Beckhoven, A., Liles, T.M., Engleman, E.G. Levy, R. (2002a) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood, 99, 1517 1526.
84. Timmerman, J.M., Singh, G., Hermanson, G., Hobart, P., Czerwinski, D.K., Taidi, B., Rajapaksa, R., Caspar, C.B., Van Beckhoven, A. Levy, R. (2002b) Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Research, 62, 5845 5852.
85. Van Slooten, M.L., Boerman, O., Romoren, K., Kedar, E., Crommelin, D.J. Storm, G. (2001) Liposomes as sustained release system for human interferon-gamma: biopharmaceutical aspects. Biochimica et Biophysica Acta, 1530, 134 145.
86. Vose, J.M. (2006) Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach. Hematological Oncology, 24, 47 55.
87. Wassef, N.M., Alving, C.R. Richards, R.L. (1994) Liposomes as carriers for vaccines. Immunomethods, 4, 217 222.
88. Weng, W.K., Czerwinski, D., Timmerman, J., Hsu, F.J. Levy, R. (2004) Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. Journal of Clinical Oncology, 22, 4717 4724. Erratum in: (2005) J Clin Oncol,23, 248.
89. Wierda, W.G., Cantwell, M.J., Woods, S.J., Rassenti, L.Z., Prussak, C.E. Kipps, T.J. (2000) CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood, 96, 2917 2924.
90. Witzig, T.E., Vukov, A.M., Habermann, T.M., Geyer, S., Kurtin, P.J., Friedenberg, W.R., White, W.L., Chalchal, H.I., Flynn, P.J., Fitch, T.R. Welker, D.A. (2005) Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. Journal of Clinical Oncology, 23, 1103 1108.
91. Yang, X. Brunham, R.C. (1998) Gene knockout B cell-deficient mice demonstrate that B cells play an important role in the initiation of T cell responses to Chlamydia trachomatis (mouse pneumonitis) lung infection. Journal of Immunology, 161, 1439 1446.
92. Yang, Z.Z., Novak, A.J., Stenson, M.J., Witzig, T.E. Ansell, S.M. (2006a) Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood, 107, 3639 3646.
93. Yang, Z.Z., Novak, A.J., Ziesmer, S.C., Witzig, T.E. Ansell, S.M. (2006b) Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Research, 66, 10145 10152.
94. Zou, W. (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Reviews Cancer, 5, 263 274.